JP2011503012A - 予後に関するバイオマーカーおよび治療の分子標的としての細胞外ヒストン - Google Patents

予後に関するバイオマーカーおよび治療の分子標的としての細胞外ヒストン Download PDF

Info

Publication number
JP2011503012A
JP2011503012A JP2010532342A JP2010532342A JP2011503012A JP 2011503012 A JP2011503012 A JP 2011503012A JP 2010532342 A JP2010532342 A JP 2010532342A JP 2010532342 A JP2010532342 A JP 2010532342A JP 2011503012 A JP2011503012 A JP 2011503012A
Authority
JP
Japan
Prior art keywords
histone
inhibitor
subject
peptide
cytotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010532342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503012A5 (cg-RX-API-DMAC7.html
Inventor
チャールズ ティー． エスモン
ジュン スー
シャオメイ チャン
Original Assignee
オクラホマ・メディカル・リサーチ・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オクラホマ・メディカル・リサーチ・ファウンデーション filed Critical オクラホマ・メディカル・リサーチ・ファウンデーション
Publication of JP2011503012A publication Critical patent/JP2011503012A/ja
Publication of JP2011503012A5 publication Critical patent/JP2011503012A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
JP2010532342A 2007-11-06 2008-11-06 予後に関するバイオマーカーおよび治療の分子標的としての細胞外ヒストン Pending JP2011503012A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98588607P 2007-11-06 2007-11-06
PCT/US2008/082632 WO2009061918A1 (en) 2007-11-06 2008-11-06 Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Publications (2)

Publication Number Publication Date
JP2011503012A true JP2011503012A (ja) 2011-01-27
JP2011503012A5 JP2011503012A5 (cg-RX-API-DMAC7.html) 2012-11-08

Family

ID=40270490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532342A Pending JP2011503012A (ja) 2007-11-06 2008-11-06 予後に関するバイオマーカーおよび治療の分子標的としての細胞外ヒストン

Country Status (6)

Country Link
US (5) US8716218B2 (cg-RX-API-DMAC7.html)
EP (1) EP2209485B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011503012A (cg-RX-API-DMAC7.html)
AU (1) AU2008323947B2 (cg-RX-API-DMAC7.html)
CA (1) CA2704974C (cg-RX-API-DMAC7.html)
WO (1) WO2009061918A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013125687A1 (ja) * 2012-02-22 2013-08-29 学校法人 城西大学 炎症疾患治療剤
JPWO2013125687A1 (ja) * 2013-02-22 2015-07-30 学校法人 城西大学 炎症疾患治療剤
US9701739B2 (en) 2010-08-20 2017-07-11 Josai University Corporation Monoclonal antibody having immunosuppressive activity or antigen binding fragment thereof
WO2018164027A1 (ja) * 2017-03-06 2018-09-13 学校法人順天堂 ヒストンによる細胞傷害を抑制するための薬剤
JP2019536062A (ja) * 2016-11-04 2019-12-12 セントロ デ インベスティガシオン ビオメディカ エン レッド 敗血症又は敗血症性ショック（ｓｓ）患者に由来する血漿中の循環ヒストンｈ３及びｈ２ｂを検出する質量分析ベースの方法
JP2020037578A (ja) * 2014-07-02 2020-03-12 インフレクティス・バイオサイエンス プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716218B2 (en) 2007-11-06 2014-05-06 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
WO2009062948A1 (en) * 2007-11-16 2009-05-22 Pronota N.V. Biomarkers and methods for diagnosing, predicting and/or prognosing sepsis and uses thereof
WO2012067152A1 (ja) * 2010-11-16 2012-05-24 三菱化学株式会社 Endothelial Protein C Receptor蛋白質による脳梗塞の検査方法
DK2646037T3 (en) 2010-12-01 2019-03-04 Univ Australian National use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
TWI442934B (zh) * 2011-03-11 2014-07-01 Univ Taipei Medical 組蛋白h4抗體的用途
WO2014127200A1 (en) 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
US10351621B2 (en) 2014-06-24 2019-07-16 Immunomedics, Inc. Anti-histone therapy in acute kidney injury
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016106387A2 (en) 2014-12-22 2016-06-30 University Of Iowa Research Foundation Nucleic acid aptamers to treat histone-induced disease states
EP3256858B1 (en) 2015-02-10 2020-03-25 B.R.A.H.M.S GmbH Histone h4 peptide as a biomarker
CN106611094B (zh) * 2015-10-15 2021-08-06 北京寻因生物科技有限公司 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统
JP6738652B2 (ja) * 2016-05-26 2020-08-12 シスメックス株式会社 試料分析方法、試料分析装置および試薬
EP3497451B1 (en) 2016-08-09 2025-06-18 B.R.A.H.M.S GmbH Histones and/or proadm as markers indicating an adverse event
US20190178897A1 (en) 2016-08-09 2019-06-13 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating organ dysfunction
CN106397575A (zh) * 2016-10-20 2017-02-15 上海懿贝瑞生物医药科技有限公司 一种具有胞外组蛋白毒性抑制作用的多肽制备方法及用途
CN110431425B (zh) 2017-02-02 2023-06-27 B.R.A.H.M.S 有限公司 proADM作为指示不良事件的标志物
EP3685165B1 (en) 2017-09-18 2022-04-20 Santersus AG Method and device for purification of blood from circulating cell free dna
GB201804833D0 (en) * 2018-03-26 2018-05-09 Univ Liverpool Pro-coagulant histones
CN110101838B (zh) * 2019-04-29 2022-07-01 陕西师范大学 一种提高组蛋白抗大肠杆菌性能的方法
CN111202839A (zh) * 2020-02-21 2020-05-29 佛山科学技术学院 一种组蛋白h4在抑制禽流感病毒中的应用
AU2021247142A1 (en) * 2020-04-03 2022-12-01 Medsenic Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals
CN112679579B (zh) * 2020-12-29 2022-02-01 潍坊医学院 一种分离自华蟾素注射液的镇痛肽ci5及其应用
WO2023126672A1 (en) 2021-12-27 2023-07-06 Santersus Ag Method and device for removal of circulating cell free dna

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007246473A (ja) * 2006-03-17 2007-09-27 Chemo Sero Therapeut Res Inst 臓器障害抑制剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4676500A (en) * 1999-04-28 2000-11-10 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus
US7528227B2 (en) * 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
US7238656B2 (en) * 2001-08-29 2007-07-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
JP4834826B2 (ja) 2003-07-22 2011-12-14 独立行政法人産業技術総合研究所 ヒストンｈ３及びｈ４リンカー領域を認識するモノクローナル抗体及びその産生ハイブリドーマ
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP2011490A1 (en) 2007-07-05 2009-01-07 Sanofi-Aventis Beta adrenergic receptor ligand derivatives for modulating apoptosis
US8716218B2 (en) * 2007-11-06 2014-05-06 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007246473A (ja) * 2006-03-17 2007-09-27 Chemo Sero Therapeut Res Inst 臓器障害抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5010015263; ＡＢＡＫＵＳＨＩＮ，Ｄ．Ｎ．　ｅｔ　ａｌ: 'ＨＩＳＴＯＮＥＳ　ＥＶＯＫＥ　ＴＨＹＭＯＣＹＴＥ　ＤＥＡＴＨ　ＩＮ　ＶＩＴＲＯ　：　ＨＩＳＴＯＮＥ-ＢＩＮＤＩＮＧ　ＩＭＭＵＮＯＧＬＯＢＵＬＩＮＳ　ＤＥＣＲＥＡＳＥ　ＴＨＥＩＲ　ＣＹＴＯＴＯＸＩＣＩＴ' ＢＩＯＣＨＥＭＩＳＴＲＹ Ｖｏｌ．６４，　Ｎｏ．６, 199906, ｐ．６９３-６９８ *
JPN6013033354; ＣＵＲＲＩＥ，Ｊ．Ｒ．　ｅｔ　ａｌ: Ｂｉｏｃｈｉｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　Ａｃｔａ Ｖｏｌ．１３５５, 1997, ｐ．２４８-２５８ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701739B2 (en) 2010-08-20 2017-07-11 Josai University Corporation Monoclonal antibody having immunosuppressive activity or antigen binding fragment thereof
WO2013125687A1 (ja) * 2012-02-22 2013-08-29 学校法人 城西大学 炎症疾患治療剤
KR20140138699A (ko) * 2012-02-22 2014-12-04 조사이 유니버시티 코포레이션 염증 질환 치료제
KR102159412B1 (ko) * 2012-02-22 2020-09-23 조사이 유니버시티 코포레이션 염증 질환 치료제
JPWO2013125687A1 (ja) * 2013-02-22 2015-07-30 学校法人 城西大学 炎症疾患治療剤
JP2020037578A (ja) * 2014-07-02 2020-03-12 インフレクティス・バイオサイエンス プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用
JP2019536062A (ja) * 2016-11-04 2019-12-12 セントロ デ インベスティガシオン ビオメディカ エン レッド 敗血症又は敗血症性ショック（ｓｓ）患者に由来する血漿中の循環ヒストンｈ３及びｈ２ｂを検出する質量分析ベースの方法
JP7173495B2 (ja) 2016-11-04 2022-11-16 セントロ デ インベスティガシオン ビオメディカ エン レッド 敗血症又は敗血症性ショック（ｓｓ）患者に由来する血漿中の循環ヒストンｈ３及びｈ２ｂを検出する質量分析ベースの方法
US11740245B2 (en) 2016-11-04 2023-08-29 Centro De Investigación Biomédica En Red (Ciber-Isciii) Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients
WO2018164027A1 (ja) * 2017-03-06 2018-09-13 学校法人順天堂 ヒストンによる細胞傷害を抑制するための薬剤

Also Published As

Publication number Publication date
US8716218B2 (en) 2014-05-06
AU2008323947B2 (en) 2014-02-20
US10238711B2 (en) 2019-03-26
US20140308289A1 (en) 2014-10-16
CA2704974C (en) 2019-06-04
US10350261B2 (en) 2019-07-16
US20180092961A1 (en) 2018-04-05
US20090117099A1 (en) 2009-05-07
US11458187B2 (en) 2022-10-04
EP2209485A1 (en) 2010-07-28
AU2008323947A1 (en) 2009-05-14
CA2704974A1 (en) 2009-05-14
US20150344556A1 (en) 2015-12-03
EP2209485B1 (en) 2016-03-30
US20190216884A1 (en) 2019-07-18
WO2009061918A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
US11458187B2 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
JP2012136536A (ja) アテローム血栓症およびプラーク破壊を予防するためのアネキシンｖ
EP3260133B1 (en) Antibodies against mac-1
JP6198277B2 (ja) 血液凝固促進に使用するための化合物
US10646556B2 (en) Methods for treatment of and prophylaxis against inflammatory disorders
KR20200116098A (ko) 항응고제 단백질 및 호중구의 활성화와 관련된 질환을 치료하기 위한 이의 용도
JP6989377B2 (ja) Ｋｖ１．３カリウムチャネルアンタゴニスト
US8173595B2 (en) Methods and compositions for the inhibition of thrombus formation
US20170042981A1 (en) Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor
JP2012224549A (ja) 抗凝固薬及びその用途
US20190092814A1 (en) Peptide
WO2008038777A1 (en) Therapeutic agent for disseminated intravascular coagulation syndrome
Bertin Leukocytes in venous thrombosis
Konatschnig et al. Targeting complement resistance on human tumours: Cloning, expression and functional characterisation of a novel chimeric anti-CD59 miniantibody
JP2009502849A (ja) 血栓症及び癌の治療、及び／又は予防のためのａｃｒｐ３０の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140630